Replies to post #8397 on The Rising Influence of Rising Affluence

[jbog]

Novo has captured > 60% of the Chinese market and I don't expect them to take a step backwards anytime soon. They have a decent presence in the country.

You always face the risk that any of these countries can and will nationalize the drugs, and I wouldn't put it past China if things become unwieldy. If Brasil, India etc keep getting around patent law it will be on all the emerging countries calender.


http://www.novonordisk.com/images/Sustainability/PDFs/Blueprint%20for%20change%20-%20China.pdf

[DewDiligence]

Do you have an investment thesis in mind to leverage off of the diabetes growth in China and India? Not a clear pathway for this that I can see.

I own ABT, which is the #2* drug company in India, although it’s not a direct play on type-2 diabetes. For several years, I’ve wanted to own NVO, but I never pulled the trigger because I thought the valuation was too high.

*ABT is technically still #1 in India until the Sun-Ranbaxy merger closes.